https://gsk-3inhibitors.com/pa....rp-inhibitors-in-pro
A complete of 140 (belotecan, n = 71; topotecan, n = 69) and 130 customers (belotecan, n = 66; topotecan, n = 64) had been included in the intention-to-treat (ITT) and per-protocol (PP) populations. ORR didn't vary somewhat between the belotecan and topotecan teams (ITT, 29.6% versus 26.1%; PP, 30.3% versus 25%). Although PFS failed to differ amongst the groups, belotecan ended up being associated with improved OS compared with topotecan within the PP population (39.7 versus 26.6 months; P = 0.034). In specific, bel
Beğen
Yorum Yap
Paylaş
